Livermore D M
Department of Medical Microbiology, London Hospital Medical College, UK.
J Antimicrob Chemother. 1993 Jan;31 Suppl A:9-21. doi: 10.1093/jac/31.suppl_a.9.
Inhibitor combinations provide one strategy to overcome beta-lactamase-mediated resistance. Their success depends, obviously, on the inhibitor being able to bind and inactivate the beta-lactamase molecules. Clavulanate, sulbactam and tazobactam are irreversible inactivators of many beta-lactamases, forming covalent complexes which resist hydrolysis. 'Suicide' kinetics are seen with some, but not all, enzymes. All three compounds inactivate staphylococcal penicillinase, the chromosomal beta-lactamases of Proteus vulgaris and Bacteroides spp., and the Class IV beta-lactamases present in some klebsiellae. Tazobactam, but not the other compounds, has moderate activity against some Class I (AmpC) chromosomal beta-lactamases, notably that of Morganella morganii, but not that of Enterobacter cloacae. Both clavulanate and tazobactam are strong inhibitors of the widely distributed TEM and SHV plasmid-mediated beta-lactamases; sulbactam is a weaker inhibitor. Other factors, aside from the affinity of the inhibitor for the enzyme, co-determine the success or failure of inhibition. Potentiation is most readily achieved if little enzyme is produced, and if the organism is very permeable to the inhibitor. Thus, resistance to inhibitor combinations is rare in strains of Haemophilus influenzae and Neisseria gonorrhoeae that produce TEM-beta-lactamase, but is commoner in enterobacteria that produce this enzyme, since these are less permeable and sometimes manufacture very large amounts of enzyme. The partner beta-lactam agent is also important. Irrespective of the inhibitor used, piperacillin is easier to protect against TEM beta-lactamases and the M. morganii Class I enzyme than are ampicillin, amoxycillin or ticarcillin. This may relate to the lower affinity of piperacillin for these enzymes, or to its greater affinity for the bacterial penicillin-binding proteins. Finally, pH can affect the degree of inhibition achieved with sulphones for some beta-lactamases, notably TEM-1.
抑制剂联合使用是克服β-内酰胺酶介导耐药性的一种策略。显然,其成功与否取决于抑制剂能否结合并使β-内酰胺酶分子失活。克拉维酸、舒巴坦和他唑巴坦是许多β-内酰胺酶的不可逆失活剂,可形成抗水解的共价复合物。部分而非全部酶呈现“自杀”动力学。这三种化合物均可使葡萄球菌青霉素酶、普通变形杆菌和拟杆菌属的染色体β-内酰胺酶以及某些克雷伯菌属中存在的IV类β-内酰胺酶失活。他唑巴坦对某些I类(AmpC)染色体β-内酰胺酶具有中等活性,尤其是摩根摩根菌的该酶,但对阴沟肠杆菌的该酶无活性,而其他两种化合物则无此作用。克拉维酸和他唑巴坦都是广泛分布的TEM和SHV质粒介导的β-内酰胺酶的强抑制剂;舒巴坦的抑制作用较弱。除了抑制剂与酶的亲和力外,其他因素共同决定抑制的成败。如果产生的酶很少,且生物体对抑制剂的通透性很高,那么最容易实现增效作用。因此,产生TEM-β-内酰胺酶的流感嗜血杆菌和淋病奈瑟菌菌株对抑制剂联合使用耐药的情况很少见,但在产生这种酶的肠杆菌中则较为常见,因为这些细菌通透性较差,有时还会产生大量的酶。与之联合的β-内酰胺类药物也很重要。无论使用何种抑制剂,与氨苄西林、阿莫西林或替卡西林相比,哌拉西林更易于抵御TEMβ-内酰胺酶和摩根摩根菌I类酶。这可能与哌拉西林对这些酶的亲和力较低,或与它对细菌青霉素结合蛋白的亲和力较高有关。最后,pH值可影响某些β-内酰胺酶(尤其是TEM-1)对砜类的抑制程度。